Annual Cash & Cash Equivalents
$14.87 M
-$210.98 M-93.42%
December 31, 2022
Summary
- As of February 10, 2025, RUBY annual cash & cash equivalents is $14.87 million, with the most recent change of -$210.98 million (-93.42%) on December 31, 2022.
- During the last 3 years, RUBY annual cash & cash equivalents has fallen by -$77.03 million (-83.82%).
Performance
RUBY Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$14.87 M
-$89.02 M-85.69%
December 31, 2022
Summary
- As of February 10, 2025, RUBY quarterly cash and cash equivalents is $14.87 million, with the most recent change of -$89.02 million (-85.69%) on December 31, 2022.
- Over the past year, RUBY quarterly cash and cash equivalents has dropped by -$210.98 million (-93.42%).
Performance
RUBY Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
RUBY Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -93.4% | -93.4% |
| 3 y3 years | -83.8% | -83.8% |
| 5 y5 years | -85.8% | -85.8% |
RUBY Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -93.4% | at low | -93.4% | at low |
| 5 y | 5-year | -93.4% | at low | -94.8% | at low |
| alltime | all time | -95.2% | -54.0% | -95.8% | at low |
Rubius Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2022 | $14.87 M(-93.4%) | $14.87 M(-85.7%) |
| Sep 2022 | - | $103.88 M(+67.0%) |
| Jun 2022 | - | $62.21 M(-36.6%) |
| Mar 2022 | - | $98.10 M(-56.6%) |
| Dec 2021 | $225.85 M(+147.7%) | $225.85 M(-14.5%) |
| Sep 2021 | - | $264.02 M(-6.8%) |
| Jun 2021 | - | $283.23 M(-1.7%) |
| Mar 2021 | - | $288.09 M(+216.0%) |
| Dec 2020 | $91.17 M | $91.17 M(+21.3%) |
| Sep 2020 | - | $75.17 M(-41.8%) |
| Jun 2020 | - | $129.16 M(-10.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2020 | - | $144.52 M(+57.3%) |
| Dec 2019 | $91.90 M(-70.1%) | $91.90 M(-16.2%) |
| Sep 2019 | - | $109.61 M(-22.3%) |
| Jun 2019 | - | $141.08 M(-26.7%) |
| Mar 2019 | - | $192.50 M(-37.3%) |
| Dec 2018 | $307.06 M(+194.4%) | $307.06 M(-13.5%) |
| Sep 2018 | - | $354.79 M(+203.4%) |
| Jun 2018 | - | $116.92 M(-14.3%) |
| Mar 2018 | - | $136.47 M(+30.9%) |
| Dec 2017 | $104.29 M(+1426.0%) | $104.29 M |
| Dec 2016 | $6.83 M | - |
FAQ
- What is Rubius Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Rubius Therapeutics?
- What is Rubius Therapeutics annual cash & cash equivalents year-on-year change?
- What is Rubius Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Rubius Therapeutics?
- What is Rubius Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Rubius Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of RUBY is $14.87 M
What is the all time high annual cash & cash equivalents for Rubius Therapeutics?
Rubius Therapeutics all-time high annual cash & cash equivalents is $307.06 M
What is Rubius Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, RUBY annual cash & cash equivalents has changed by -$210.98 M (-93.42%)
What is Rubius Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of RUBY is $14.87 M
What is the all time high quarterly cash and cash equivalents for Rubius Therapeutics?
Rubius Therapeutics all-time high quarterly cash and cash equivalents is $354.79 M
What is Rubius Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, RUBY quarterly cash and cash equivalents has changed by -$210.98 M (-93.42%)